학술논문
Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus.
Document Type
article
Author
Salvadori, Nicolas; Fan, Bo; Teeyasoontranon, Waralee; Ngo-Giang-Huong, Nicole; Phanomcheong, Siriluk; Luvira, Anita; Puangsombat, Achara; Suwannarat, Arunrat; Srirompotong, Ussanee; Putiyanun, Chaiwat; Cressey, Tim; Decker, Luc; Khamduang, Woottichai; Harrison, Linda; Tierney, Camlin; Shepherd, John; Kourtis, Athena; Bulterys, Marc; Siberry, George; Jourdain, Gonzague
Source
Clinical Infectious Diseases. 69(1)
Subject
Language
Abstract
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.